GERN Geron Corp.

$GERN ACCUMULATE cheapies, shorts are doing there best to knock it down, but they will get their ugly face ripped off...IMO, 2027 is going to a banner year! Now is the time to load up on this little gem if you can and hodl for longterm capital appreciation! NFA,LG!

$GERN Plenty of cash in bank, demand, sales and revenue growing at healthy rate. Profitability right around the corner and plenty of catalysts on the horizon. It is definitely a time to buy and not panic sell. The whole sector was down today. There is nothing wrong with GERN.

$GERN Well, I had to re-enter here at 1.24. Gobbled 15k shares to start. Seriously ..... Earnings are in 6 weeks and expectations WILL be high. I don't know if earnings will beat, but the expectations should drive this much higher leading into earnings.

$GERN I honestly do not get it. Revenue up Net income stil negative, but far less than last quarter. Some MM's must just be working hard to manupulate this, until they pull the trigger and it rockets. Oh wait....they don't even need to watch...AI does all the work

$GERN Info from AI: While myelofibrosis (MF) is a considerably smaller patient pool than lower-risk myelodysplastic syndromes (LR-MDS), a positive/brilliant result of Geron's IMpactMF trial will revolutionize blood cancer treatment because it will "provide clinical validation that imetelstat is a potent disease-modifying agent ... and it [will] act as a powerful 'proof of concept' for imetelstat's biological mechanism, lending immense credibility to its pipeline potential in tougher indications like AML." AML, keep in mind, is a huge market.

$GERN I read the following on AI regarding the IMpactMF trial but am not sure what it means: "If Geron delivers a raw hazard ratio of, say, 0.60, but a pharma buyer applies a crossover-adjustment model showing that the true hazard ratio without crossover would have been 0.45, the scientific validation is complete. A buyer will pay a premium for a drug that proves it can rescue patients where an older control arm completely failed."

$GERN ACCUMULATE CHEAPIES! F the shorts controlling the down side! Q3 numbers, when released, WE ROCK...LG!

$GERN Does anyone have any idea why Geron's stock is trading below $2 per share? Is it manipulation by big players who want the stock for a low price now because they believe it'll zoom up by mid-2027? Or is the reason less positive? This price makes no sense on the surface.

$GERN We have been here before at the lows and always shoot back to the $1.50 - $1.60 level. Buy the dip and wait for the next earnings which i believe comes out in early Nov. Good luck to all.

$GERN Referencing a previous comment, a successful IMpactMF trial heralds excellent news for treating AML -- not just MF -- because of the trial's proof of disease modification, and AML is a huge market; moreover, a powerful and influential Big Pharma could submit their AML trial results upon completing phase 2, or as AI Claude states: "By skipping the traditional, slow-moving, de-novo Phase 3 roadmap for secondary indications, a well-resourced Geron buyer can fast-track imetelstat into frontline and acute settings at a fraction of the cost, turning their acquisition into a multi-indication powerhouse efficiently."

$GERN It's done almost 18 million shares in after hours the last 3 trading evenings. Someone's doing some trading.

$GERN Every time GERN goes down it rocket shoot back up again. Buy the lows. Profit on the high.

$GERN The latest earnings call analysis points to a stronger commercial run-rate for RYTELO: second-quarter 2026 net revenue was $57.5M, up 17% year over year and 11% quarter over quarter, and management said it expects full-year 2026 RYTELO revenue to land at the mid to high end of $220M–$240M. It also highlighted a 4% year-over-year decline in first-half operating expenses, suggesting tighter cost control alongside growth. Just saying

$GERN Reality check. Way undervalued IMHO. 🤓 The Paradox: Cytopenias Predict Clinical Success In a fascinating clinical paradox highlighted in data presented at the American Society of Hematology (ASH) annual meeting, the early onset of treatment-emergent cytopenias was actually associated with a greater likelihood of clinical benefit. Patients who experienced early drops in white blood cells and platelets often went on to experience the highest increases in hemoglobin and the longest periods of transfusion independence. This suggests that cytopenias serve as a biological marker that the drug is successfully eliminating the malignant clones in the bone marrow. 🧑‍⚕️👀

$GERN these monthly bolinger bands dont get much tighter then this, nice monthly candle next month and we confirm the uptrend on the monthly. its coming…

$GERN Still millions being traded after hours. Almost everyday and no movement. Scheduled trades

$GERN Just the lull between Qs, we'll see some nice upside action as we approach late October, unless they release other positive news between now and than! IMO, not much downside from here since we filled the $1.28 gap recently...Accumulate GERN cheapies if you can.

$GERN $7 trillion in options expired today. That's how much came off the books. I would say that had something to do with closing.

$GERN IOVA & GERN are both bio stocks, very similar with great increase revenue & near true profitability. But IOVA has rocket double in price and GERN continue to flounder in price. Someday soon, watch out when GERN really finally get notice. We see when the next earnings come out. Best to to shareholders.

$GERN 88% institutional ownership(fintel).. these classic manipulation games on sp to toy with the emotions of retail traders.. this has been a long road, but this is a long play.. know what you own and don't whine if you can't be patient..